12 February 2020 . Takis has applied to the European Call: “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic” with the project
“EUIMMUnCoV: The European Immunotherapy Platform against 2019-nCoV”.
EUIMMUnCoV project aims at developing novel and effective gene-based vaccines that activate the immune response against 2019-nCoV by means of innovative genetic strategies based on gene engineering and a multi-purpose and efficient device based on the mechanism of in vivo electroporation mediated gene transfer (EGT) which is already present in the hospitals of most European Countries. The same technology will be used to generate diagnostic and therapeutic antibodies able to block 2019-nCoV replication and propagation. Very importantly, EUIMMUnCoV will characterize host immune response against the virus, thus generating new knowledge important to identify new biomarkers.
If funded, Takis will coordinate a consortium made of 5 public/private partners:
- IGEA (Italy)
- Meditox (Czeck Republic)
- National Institute for Infectious Diseases (INMI) Spallanzani (Italy)
- Medical University of Vienna (Austria)
- Immunitrack (Denmark)